Phaseline

Companies › Alto Neuroscience

Alto Neuroscience: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 2; Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALTO-300–Phase 2Major Depressive DisorderDec 2026
ALTO-100–Phase 2Bipolar Disorder I or II With a Major Depressive EpisodeSep 2027
ALTO-207–Phase 2Treatment-resistant Depression (TRD)Nov 2027
ALTO-101–Phase 2Schizophrenia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06502964ALTO-101Phase 2SchizophreniaPsychiatryFeb 2026
NCT05922878ALTO-300Phase 2Major Depressive DisorderPsychiatryDec 2026
NCT06656416ALTO-100Phase 2Bipolar Disorder I or II With a Major Depressive EpisodePsychiatrySep 2027
NCT07553637ALTO-207Phase 2Treatment-resistant Depression (TRD)PsychiatryNov 2027

From the company's SEC filings

Cash of $244m on 2026-06-30; operating cash outflow about $95m a year; runway about 31 months at that burn, to Jan 2029; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Seaport Therapeutics LB Pharmaceuticals Definium Therapeutics US Anavex Life Sciences Draig Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.